SPEECH BY THE HON. LOUIS DEGUARA, MINISTER OF HEALTH, THE ELDERLY AND COMMUNITY CARE, AT THE ANNUAL INTERNATIONAL GENERIC PHARMACEUTICAL ALLIANCE CONFERENCE ORGANISED BY THE MALTA ENTERPRISE – ST. JULIANS – 20 JUNE 2005
Ladies and gentlemen,
I would like to thank you for choosing the island of Malta as the venue for the biggest conference spanning the generic pharmaceutical sector. Although Malta is a small country, it has a long and rich history of excellence in the health care sector.
Between 1530 and 1798, Malta was ruled by the Order of the Knights of St John. The Order prided itself on the care of the sick, so much so that the second most important official in the Order’s hierarchy was the Grand Hospitallier. The Sacra Infermeria in Valletta , which today houses the Mediterranean Conference Centre, was considered one of the best hospitals in Europe . Later, it was no coincidence that during the First World War Malta earned itself the eponym “Nurse of the Mediterranean ” since it was to this island that thousands of wounded soldiers were brought to be nursed and cared for.
Malta has maintained its reputation of excellence in health care as demonstrated by the very high health status of our population. Furthermore, in 2000, Malta placed fifth in the World Health Organisation’s ranking of health care systems. Although healthcare in Malta is provided via two systems- statutory and private - surveys have repeatedly shown that the Government-run health service is highly esteemed by the population. We have not rested on the laurels of our success and are currently finishing a state of the art hospital, Mater Dei Hospital, to continue to guarantee the highest standards of medical care for the Maltese population.
Modern medicine relies increasingly on the use of pharmaceuticals to achieve therapeutic objectives. Medicines have replaced surgery in the treatment of a number of conditions. They have penetrated our lives to such an extent that the use of medicines is not only associated with illness but has become very important in primary and secondary prevention. We have also seen the introduction of medicines known as “lifestyle medicines”. The ubiquitous nature of medicines in healthcare places a responsibility on the health authorities for ensuring that the medicines available to the public are safe, effective and of good quality.
One of the key areas that have undergone major reforms as part of Malta ’s accession to the European Union is undoubtedly the pharmaceutical sector. During the last three years my Ministry has set up the necessary legislation in the form of a Medicines Act with its accompanying subsidiary legislation. We have also set up the competent authority to regulate pharmaceuticals in line with the requirements of the European Union. The setting up of this authority was important in boosting local confidence in generics since generic medicines undergo the necessary scrutiny prior to registration. Major changes have taken place in a short span of time. These changes did not only affect Government as the regulator but also affected the local pharmaceutical industry. I am pleased to say that the manufacturing industry has embraced these challenges and has undergone spectacular transformation such that our local companies conform to the highest standards as laid down by EU requirements.
Of course there is a relatively considerable public resource burden associated with pharmaceutical regulation in a small country. One negative impact of the requirements of medicines regulation has been a substantial reduction in the number of registered medicines registered on our market resulting in a decrease in the number of medicines available locally. It is hoped that with the implementation of article 126a of directive 2004/27, this shortage will be effectively addressed.
However we have invested in this sector since we know how important it is for the local pharmaceutical industry to have a serious and credible regulatory authority in the field.
Our second major responsibility as the Ministry for Health is the provision of medicines required by the public health care sector. Maltese suffering from chronic diseases usually choose to access the public sector hospitals and rehabilitation services. Unlike most other new member states, Malta has no co-payment or reimbursement system for public health care. The national health service offers universal entitlement for medicines required for inpatient use. In addition it also provides medicines for those in low-income groups and for persons suffering from many chronic diseases. These medicines are all provided totally free of charge to the consumer.
As has happened in other countries, Malta has witnessed inexorably rising expenditure on medicines for the public sector. This expenditure now accounts for 20% of recurrent expenditure by government on health. My Ministry is therefore actively pursuing strategies to ensure financial sustainability in this sector.
This Government believes that the generic medicines industry has a pivotal role to play in making medicines more affordable. In the public sector, we pursue a policy of procuring generic medicines, where these are available, because of the significant price difference between the originator and the generic version. It is heartening to note that around one third of medicinal products currently being registered by our medicines authority are generics. We are now seeing an expansion of use of generic medicines in the private sector, and it is my belief that local generics pharmaceutical companies are being instrumental in making sure that generics appear in a regular fashion on the shelves of private retail pharmacies.
This generics pharmaceutical sector in Malta today employs over 500 employees and in the next two years this is expected to double. Some of the companies we have attracted to Malta are among the participants of this conference; Actavis, Siegfried, Arrow, CombinoPharm, Amino, Medichem and others are clear proof of Malta’s global competitiveness in the production of pharmaceuticals. My Ministry leaves no stone unturned to support these enterprises.
Finally, the recent Pharmaceutical review conducted by the European Union leading to the publication of new legislation has had some favourable points for generics such as the introduction of the European Reference Generic product. Whilst we welcome this initiative, we were somewhat concerned about the extension of the period of data exclusivity from six to ten years and believe that as a new Member State more time is required for us to adapt before implementing this ten-year period.
I believe that we have succeeded in building the necessary infrastructure both to support and regulate industry. As you can see, ladies and gentlemen, Malta is proving to be at the forefront in the pharmaceutical sector and its success as a nucleus of such activity is mirrored in the accomplishments that established firms are already making.
I augur that you will have a successful conference and hope that you also find some time to enjoy our island’s heritage.
Ladies and gentlemen, thanks.
Other Press Releases:
PR261947
STQARRIJA MILL-UFFIĊĊJU TAD-DEPUTAT PRIM MINISTRU U MINISTERU GĦAS-SAĦĦA Ċ...
PR261946